Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Systemic Review of Malpractice Litigation in the Diagnosis and Treatment of Acute Stroke
Stroke 50:2858-2864, Haslett, J.J.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Clinicopathologic Conference, Adenovirus Meningoencephalitis
NEJM 381:1459-1470, Case 31-2019, 2019
Intravenous Thrombolysis for Suspected Ischemic Stroke with Seizure at Onset
Ann Neurol 86:770-779, Polymeris, A.A.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Neurol 93:975-977, Barghouthi, T.,et al, 2019
Pes Cavus and Neuropathy
Neurol 93:e823-e826, Alderson,J.,& Ghosh,P.S., 2019
Dupuytren, Ledderhose, and Peyronie Diseases after Primidone Use for Essential Tremor
Neurologist 24:150-151, Felipe, L.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Recommendations for the Establishment of Stroke Systems of Care
Stroke 50:e1-e24, Adeoye, O.,et al, 2019
Imaging Findings After Mechanical Thrombectomy in Acute Ischemic Stroke
Stroke 50:1618-1625, Puntonet, J.,et al, 2019
Subacute Progressive Sensorimotor Symptoms
BMJ 365:doi:10.1136/bmj.l1923, Francis, A.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
Penumbra Detection in Acute Stroke with Perfusion Magnetic Resonance Imaging: Validation with 15 O-Positron Emission Tomography
Ann Neurol 85:875-886, Zaro-Weber, O.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Extending Thrombolysis to 4.5-9 h and Wake-Up Stroke Using Perfusion Imaging: A Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 394:139-147,97, Campbell, B.C.V.,et al, 2019
Thrombus Length Predicts Lack of Post-Thrombolysis Early Recanalization in Minor Stroke With Large Vessel Occlusion
Stroke 50:761-764, Seners, P.,et al, 2019
Magnetic Resonance Imaging Versus Computed Tomography Angiography Based Selection for Endovascular Therapy in Patients with Acute Ischemic Stroke
Stroke 50:365-372, Kim, J-T.,et al, 2019
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Impact of Microbleeds on Outcome Following Recanalization in Patients with Acute Ischemic Stroke
Stroke 50:127-134, Choi, K.H.,et al, 2019
The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Central Nervous System Infections Due to Coccidioidomycosis
J Fungi 5:2-12, Jackson, N.R.,et al, 2019
Cerebellar Hippocampal and Basal Nuclei Transient Edema with Restricted Diffusion (CHANTER) Syndrome
Neurocrit Care 31:228-296, Jasne, A.S.,et al, 2019
Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum
Emerg Inf Dis 25:1648-1652, Nookeu,P.,et al, 2019
Basa Ganglia Calcifications (Fahrs Syndrome): Related Conditions and Clinical Features
Neurol Sci 40:2251-2263, Donzuso,G.,et al, 2019
Clinical Manifestations and Diagnosis of Nocardiosis
UptoDate May, Spelman, D., 2019
Vascular Wall Imaging in Reversible Cerebral Vasoconstriction Syndrome - a 3-T Contrast-Enhanced MRI Study
J Headache Pain 19:74-81, Chen, C.Y.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma
Case Rep Neurol Med 2018;doi:10.1155/2018/2548528, Shah, S.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute Amnestic Syndrome Associated with Fentanyl Overdose
NEJM 378:1157-1158, Barash, J.A., et al, 2018
Interventions for Improving Modifiable Risk Factor Control in the Secondary Prevention of Stroke
Stroke 49:e301-e302, Bridgwood, B.,et al, 2018
Mechanical Thrombectomy Outcomes with or without Intravenous Thrombolysis
Stroke 49:2383-2390, Gariel, F.,et al, 2018
Endovascular Stroke Therapy in the Late Time Window
Stroke 49:2559-2561, Schellinger, P.D. & Demaerschalk, B.M., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Surviving Cerebral Malaria
Neurol 91:978-979, Wijdicks, E.F.M. & Park, J.G., 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018